The influence of subclonal resistance mutations on targeted cancer therapy

Nature Reviews Clinical Oncology

Volumn 13, Issue 6, 2016, Pages 335-347

  Schmitt, Michael W ^a,b   Loeb, Lawrence A ^a   Salk, Jesse J ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ALPHA INTERFERON; ARSENIC; BOSUTINIB; CERITINIB; CETUXIMAB; CRIZOTINIB; CYTARABINE; DABRAFENIB; DASATINIB; ERLOTINIB; GEFITINIB; GEMCITABINE; IBRUTINIB; IMATINIB; LAPATINIB; NILOTINIB; OLAPARIB; PANITUMUMAB; PERTUZUMAB; PONATINIB; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TRAMETINIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VEMURAFENIB; ARG TYROSINE KINASE; B RAF KINASE; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL HETEROGENEITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; DRUG TREATMENT FAILURE; ESOPHAGEAL ADENOCARCINOMA; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; MELANOMA; MISMATCH REPAIR; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NON SMALL CELL LUNG CANCER; PANCREAS CANCER; PERSONALIZED MEDICINE; PML GENE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RARA GENE; REVIEW; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; MUTATION; NEOPLASMS; PROCEDURES; PROTO ONCOGENE; SIGNAL TRANSDUCTION;

DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENES, ERBB-1; HUMANS; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84944916590     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.175     Document Type: Review

References (125)

1. Schmitt M. W., Prindle M. J., & Loeb L. A. Implications of genetic heterogeneity in cancer. Ann. N. Y. Acad. Sci. 1267, 110-116 (2012
2. Alexandrov L. B., et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013
3. Lawrence M. S., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013
4. Cull E. H., & Altman J. K. Contemporary treatment of APL. Curr. Hematol. Malig. Rep. 9, 193-201 (2014
5. Welch J. S., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264-278 (2012
6. Zhu H. H., Qin Y. Z., & Huang X. J. Resistance to arsenic therapy in acute promyelocytic leukemia. N. Engl. J. Med. 370, 1864-1866 (2014
7. Loeb L. A., Springgate C. F., & Battula N. Errors in DNA replication as a basis of malignant changes. Cancer Res. 34, 2311-2321 (1974
8. Greaves M., & Maley C. C. Clonal evolution in cancer. Nature 481, 306-313 (2012
9. Nowell P. C. The clonal evolution of tumor cell populations. Science 194, 23-28 (1976
10. Hanahan D., & Weinberg R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011
11. Berger M. F., et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485, 502-506 (2012
12. Campbell P. J., et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc. Natl Acad. Sci. USA 105, 13081-13086 (2008
13. Ding L., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-509 (2012
14. Gerlinger M., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012
15. Naxerova K., et al. Hypermutable DNA chronicles the evolution of human colon cancer. Proc. Natl Acad. Sci. USA 111, E1889-E1898 (2014
16. Mullighan C. G., et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377-1380 (2008
17. Landau D. A., et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013
18. Rossi D., et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 123, 2139-2147 (2014
19. Wong T. N., et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518, 552-555 (2015
20. Bhang H. E., et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21, 440-448 (2015
21. Mroz E. A., et al. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer 119, 3034-3042 (2013
22. Mroz E. A., Tward A. M., Hammon R. J., Ren Y., & Rocco J. W. Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from The Cancer Genome Atlas. PLoS Med. 12, e1001786 (2015
23. Cooke S
24. Park S. Y., Gonen M., Kim H. J., Michor F., & Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J. Clin. Invest. 120, 636-644 (2010
25. Carter S. L., Eklund A. C., Kohane I. S., Harris L. N., & Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 38, 1043-1048 (2006
26. Merlo L. M., et al. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev. Res. (Phila.) 3, 1388-1397 (2010
27. Wang Y., et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512, 155-160 (2014
28. Foulkes W. D., Reis-Filho J. S., & Narod S. A. Tumor size and survival in breast cancer - a reappraisal. Nat. Rev. Clin. Oncol. 7, 348-353 (2010
29. Sinicrope F. A., & Yang Z. J. Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer. Future Oncol. 7, 467-474 (2011
30. Fox E. J., & Loeb L. A. Lethal mutagenesis: targeting the mutator phenotype in cancer. Semin. Cancer Biol. 20, 353-359 (2010
31. Snyder A., et al. Genetic basis for clinical response to CTLA 4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014
32. Le D. T., et al. PD 1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015
33. Chereda B., & Melo J. V. Natural course and biology of CML. Ann. Hematol. 94 (Suppl. 2), S107-S121 (2015
34. Cilloni D., & Saglio G. Molecular pathways: BCR-ABL. Clin. Cancer Res. 18, 930-937 (2012
35. Druker B. J., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006
36. Moorman A. V., et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 109, 3189-3197 (2007
37. Lee K. H., et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 19, 1509-1516 (2005
38. Soverini S., et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leukemia Res. 38, 10-20 (2014
39. Roche-Lestienne C., et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014-1018 (2002
40. Roche-Lestienne C., Laï J. L., Darré S., Facon T., & Preudhomme C. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N. Engl. J. Med. 348, 2265-2266 (2003
41. Pfeifer H., et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with De novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 110, 727-734 (2007
42. Shah N. P., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125 (2002
43. Hughes T., et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J. Clin. Oncol. 27, 4204-4210 (2009
44. Fox E. J., Reid-Bayliss K. S., Emond M. J., & Loeb L. A. Accuracy of next generation sequencing platforms. Next Gener. Seq. Appl. 1, 1000106 (2014
45. Parker W. T., et al. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. J. Clin. Oncol. 29, 4250-4259 (2011
46. Parker W. T., Ho M., Scott H. S., Hughes T. P., & Branford S. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood 119, 2234-2238 (2012
47. Rubin B. P., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61, 8118-8121 (2001
48. Lennartsson J., & Ronnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol. Rev. 92, 1619-1649 (2012
49. Corless C. L., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 23, 5357-5364 (2005
50. Blanke C. D., et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 26, 620-625 (2008
51. Heinrich M. C., et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. 24, 4764-4774 (2006
52. Guo T., et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin. Cancer Res. 13, 4874-4881 (2007
53. Heinrich M. C., et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J. Clin. Oncol. 26, 5360-5367 (2008
54. Heinrich M. C., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342-4349 (2003
55. Tomasetti C., Demetri G. D., & Parmigiani G. Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors. F1000Res. 2, 152 (2013
56. Patel S. Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway. Curr. Oncol. Rep. 15, 386-395 (2013
57. Baker N. M., & Der C. J. Cancer: drug for an 'undruggable' protein. Nature 497, 577-578 (2013
58. Shi Y., et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non small cell lung cancer of adenocarcinoma histology (PIONEER). J. Thorac. Oncol. 9, 154-162 (2014
59. Zhou C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non small cell lung cancer (OPTIMAL, CTONG 0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735-742 (2011
60. Yang J. C., et al. Clinical activity of afatinib in patients with advanced non small cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 16, 830-838 (2015
61. Fukuoka M., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non small cell lung cancer in Asia (IPASS). J. Clin. Oncol. 29, 2866-2874 (2011
62. Moore M. J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966 (2007
63. Wang J. P., et al. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget 6, 18162-18173 (2015
64. Seo J. S., et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 22, 2109-2119 (2012
65. Zhou Q., et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non small cell lung cancer. J. Clin. Oncol. 29, 3316-3321 (2011
66. Lee J. K., et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor. JAMA 311, 1430 (2014
67. De Bruin E. C., et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014
68. Zhang J., et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256-259 (2014
69. Balak M. N., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12, 6494-6501 (2006
70. Chong C. R., & Janne P. A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 19, 1389-1400 (2013
71. Su K. Y., et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non small cell lung cancer. J. Clin. Oncol. 30, 433-440 (2012
72. Lee Y., et al. Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations. Cancer 120, 2090-2098 (2014
73. Karapetis C. S., et al. K ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008
74. Dolgin E. FDA narrows drug label usage. Nature 460, 1069 (2009
75. Riely G. J., Marks J., & Pao W. KRAS mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc. 6, 201-205 (2009
76. Misale S., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536 (2012
77. Molinari F., et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin. Cancer Res. 17, 4901-4914 (2011
78. Dono M., et al. Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer. Mol. Med. 18, 1519-1526 (2012
79. Tougeron D., et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann. Oncol. 24, 1267-1273 (2013
80. Long G. V., et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29, 1239-1246 (2011
81. Su F., et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215 (2012
82. Robert C., et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30-39 (2015
83. Flaherty K. T., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703 (2012
84. Long G. V., et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386, 444-451 (2015
85. Long G. V., et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat. Commun. 5, 5694 (2014
86. Girotti M. R., et al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell 27, 85-96 (2015
87. Bottema C. D., & Sommer S. S. PCR amplification of specific alleles: rapid detection of known mutations and polymorphisms. Mutat. Res. 288, 93-102 (1993
88. Tost J., & Gut I. G. Genotyping single nucleotide polymorphisms by MALDI mass spectrometry in clinical applications. Clin. Biochem. 38, 335-350 (2005
89. Bielas J. H., & Loeb L. A. Quantification of random genomic mutations. Nat. Methods 2, 285-290 (2005
90. Day E., Dear P. H., & McCaughan F. Digital PCR strategies in the development and analysis of molecular biomarkers for personalized medicine. Methods 59, 101-107 (2013
91. Schmitt M. W., et al. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl Acad. Sci. USA 109, 14508-14513 (2012
92. Kinde I., Wu J., Papadopoulos N., Kinzler K. W., & Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl Acad. Sci. USA 108, 9530-9535 (2011
93. Lou D. I., et al. High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing. Proc. Natl Acad. Sci. USA 110, 19872-19877 (2013
94. Schmitt M. W., et al. Sequencing small genomic targets with high efficiency and extreme accuracy. Nat. Methods 12, 423-425 (2015
95. Klco J. M., et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 25, 379-392 (2014
96. Bettegowda C., et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci. Transl. Med. 6, 224ra24 (2014
97. Zill O. A., et al. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov. http://dx.doi.org/10.1158/2159-8290CD 15 0274 (2015
98. Lebofsky R., et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol. Oncol. 9, 783-790 (2015
99. Piotrowska Z., et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 5, 713-722 (2015
100. Siravegna G., et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795-801 (2015
101. Thress K. S., et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21, 560-562 (2015
102. Diaz L. A., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540 (2012
103. Bardelli A., et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3, 658-673 (2013
104. Maheswaran S., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366-377 (2008
105. Yu M., et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345, 216-220 (2014
106. Chu S., et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105, 2093-2098 (2005
107. Kim T. M., et al. Regional biases in mutation screening due to intratumoural heterogeneity of prostate cancer. J. Pathol. 233, 425-435 (2014
108. Kumar A., et al. Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes. Genome Biol. 15, 530 (2014
109. Montagut C., et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 18, 221-223 (2012
110. Lee M. S., & Kopetz S. Current and future approaches to target the epidermal growth factor receptor and its downstream signaling in metastatic colorectal cancer. Clin. Colorectal Cancer http://dx.doi.org/10.1016/j.clcc.2015.05.006 (2015
111. Byrd J. C., et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 371, 213-223 (2014
112. Byrd J. C., et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125, 2497-2506 (2015
113. Advani R. H., et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI 32765) has significant activity in patients with relapsed/refractory B cell malignancies. J. Clin. Oncol. 31, 88-94 (2013
114. Woyach J. A., et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N. Engl. J. Med. 370, 2286-2294 (2014
115. Chiron D., et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 4, 1022-1035 (2014
116. Daver N., et al. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood 125, 3236-3245 (2015
117. Das Thakur M., et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251-255 (2013
118. Pattabiraman D. R., & Weinberg R. A. Tackling the cancer stem cells - what challenges do they pose? Nat. Rev. Drug Discov. 13, 497-512 (2014
119. Jordan C. T. Cancer stem cells: controversial or just misunderstood? Cell Stem Cell 4, 203-205 (2009
120. Willis S. G., et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 106, 2128-2137 (2005
121. Nucifora G., Larson R. A., & Rowley J. D. Persistence of the 8; 21 translocation in patients with acute myeloid leukemia type M2 in long term remission. Blood 82, 712-715 (1993
122. Beckman R. A., & Loeb L. A. Efficiency of carcinogenesis with and without a mutator mutation. Proc. Natl Acad. Sci. USA 103, 14140-14145 (2006
123. Bielas J. H., Loeb K. R., Rubin B. P., True L. D., & Loeb L. A. Human cancers express a mutator phenotype. Proc. Natl Acad. Sci. USA 103, 18238-18242 (2006
124. Kumar A., et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl Acad. Sci. USA 108, 17087-17092 (2011
125. Shlien A., et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat. Genet. 47, 257-262 (2015